Navigation Links
Nuvelo Announces Publication of Preclinical Study Results,Demonstrating the Potential of NTB-A as a New Target for Leukemia,and Lymphomas

SAN CARLOS, Calif., June 05, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced the publication of data from a preclinical study of novel monoclonal antibodies against the cell-surface protein NTB-A. The data demonstrate that NTB-A is a potential new target for immunotherapy of B-cell malignancies including leukemia and lymphomas. The study, entitled "The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukemia and lymphoma therapeutics," appears in the May issue of British Journal of Haematology.

Leukemia and lymphomas are malignancies of lymphoid cells. Monoclonal antibodies, in addition to chemotherapy, have been shown to be effective in eliminating lymphocytes in leukemia and lymphoma patients (1,2,3,4). However, a significant number of patients relapse after initial responses and eventually become resistant to existing therapies.

"The development of new antibody therapeutics is an important area of study as leukemia and lymphoma patients need more treatment options. This study not only lays the scientific foundation for continued NTB-A target and antibody development, but it also validates the focus of our cancer antibody research and moves us closer to identifying a lead candidate from this program," said Walter Funk, Ph.D., vice president of research for Nuvelo. "In addition to pursuing the NTB-A target, we are also studying other monoclonal antibody targets in blood cell malignancies and solid tumor cancers, and have established collaborations with leading clinical centers that support our ongoing preclinical program."

NTB-A is a CD2-related cell surface protein expressed primarily on lymphoid cells including B-lymphocytes from chronic lymphocytic leukemia (CLL) and lymphoma patients. Nuvelo has generated a series of monoclonal antibodies against NTB-A and assessed their therapeutic potential for treating CLL and lymphoma through preclinical tri
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/3/2015)... , Aug. 3, 2015  Sage Analytics ( www.sageanalytics.com ... laboratory-quality cannabis potency measurement systems, announced its sponsorship of ... Cruise Fundraiser. A limited number of tickets are available ... help a great cause while enjoying an open bar, ... around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, ... and development agreements between biotech companies, military ... biotech solutions & therapies with regards to ... to positive clinical enhancements for regenerative medicine ... with recent developments, partnerships and advancements in ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6
... 11 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... 6th Annual Healthcare Conference on Wednesday, November 18, at 8:30 ... may access a live webcast of the presentation on our ... It is recommended that listeners log on 15 minutes early ...
... NEW YORK, Nov. 11 Pulmo BioTech Inc. (OTC ... early experimental results have indicated that its PulmoBind(TM) product ... and follow-up of many conditions that affect the physical ... results, if confirmed by further experiments, would broaden the ...
Cached Medicine Technology:Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 2Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 3Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 4
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... the Atlanta Journal Constitution, the new Lifetime reality series, “Atlanta Plastic” is getting ... and who receives plastic surgery, with its predominantly African-American cast of doctors and ...
(Date:8/3/2015)... Los Angeles, California (PRWEB) , ... August 03, ... ... the Fifth Circuit Court of Appeals ruled in favor of the firm’s client ... Act ), North Cypress Medical Center must reimburse benefits for Hamsher’s residential treatment ...
(Date:8/3/2015)... Irving, Texas (PRWEB) , ... August 03, 2015 ... ... awarded an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and ... care and reduce health care costs. , Annually, more than 8.6 million ...
(Date:8/3/2015)... ... , ... Dental practice in Los Angeles , Sunset Plaza Dental, is ... general health emergencies, such as broken arms or a heart attack, should be evaluated ... to during a dental emergency. This is important, because dental trauma is extremely common. ...
(Date:8/3/2015)... Florida (PRWEB) , ... August 03, 2015 , ... ... for Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis ... , Fifty-five percent of respondents said they agreed or strongly agreed that the ...
Breaking Medicine News(10 mins):Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3
... near green spaces such as park and lawns in their ... said a US study. ,Researchers studied 7,334 children, ... and used body mass index to determine which children were ... green space and the number of food outlets such as ...
... perfect golf swing could lie in your big toe. Or your ... American College// of Foot and Ankle Surgeons (ACFAS) say these are ... that can ruin your golf swing. ,Behind these ... damage. But pain relief is possible and frequently does not require ...
... Administration ordered the makers of ADHD drugs to indicate the ... psychiatric and cardiovascular risks. ,Dr. Steven Galson, director ... that although these drugs are immensely useful in treating patients ... the public. He also said that FDA is working ...
... about that shared experience are likely more satisfied with ... of experience to draw on, according to research by ... ,The study, conducted by Doris G. Bazzini and three ... issue of the journal Motivation and Emotion. ...
... Some men who become impotent after prostate cancer surgery may ... into the penis,// which assists in restoring the lost erectile ... ,These findings came to light after a study of nearly ... restore erectile function, following its loss after treatment for prostate ...
... 30 years as the director of the Johns Hopkins Brady ... Faisal Foundation for his pioneering work in the area of ... the Saudi royal family and director of the King Faisal ... Prize at an awards ceremony in Riyadh on Jan. 16. ...
Cached Medicine News:Health News:Foot Pain Ruining Your Golf Swing? 2Health News:Researcher Studies Benefits of Reminiscing About Laughter 2Health News:Patrick Walsh Wins International Medicine Prize 2
... is one of the world's ... with a 7 F introducer, ... is designed to lower the ... allow introduction in smaller, more ...
... The Model 6491 unipolar ... designed for temporary atrial and ... and after cardiac surgery. This ... downsized, making it the ideal ...
The CapSureFix line of pacing leads combines the benefits of steroid-eluting technology with screw-in active fixation, to allow long-lasting, low-threshold delivery of pacing therapies....
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Medicine Products: